Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
One-cycle blinatumomab before allo-HSCT in adult MRD-positive or relapsed/refractory B-ALL
ChiCTR2300072593Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jun 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Shenzhen Second People's Hospital. Primary endpoint: 2-year cumulative incidence of relapse after transplantation. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on ChiCTR2300072593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072593.